Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLCGuruFocus · Oct 7, 2026
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLCBusiness Wire · Oct 7, 2026
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct OfferingBusiness Wire · Sep 30, 2026
Lantern Pharma Inc. Announces up to $8 Million Registered Direct OfferingBusiness Wire · Sep 29, 2026
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development TranscriptSeeking Alpha · Sep 23, 2026
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ETGuruFocus · Sep 23, 2026Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.38 | -$0.57 | Miss |
| May 15, 2026 | -$0.36 | -$0.30 | Beat |
| Mar 30, 2026 | -$0.46 | -$0.36 | Beat |
| Nov 12, 2025 | -$0.46 | -$0.39 | Beat |
| Aug 13, 2025 | -$0.53 | -$0.40 | Beat |
| May 15, 2025 | -$0.49 | -$0.42 | Beat |